Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of combined use of atorvastatin and hormonal therapy on serum prostate-specific antigen, urinary function, and quality of life of early prostate cancer patients in intensive care unit

Li Xiao¹, Jiaoe Liao²

¹Department of Critical Care Medicine Area 1, Chenzhou First People's Hospital, Chenzhou 423000, Hunan Province, China; ²Endocrine Diabetes Department Zone 2, Chenzhou First People's Hospital, Chenzhou 423000, Hunan Province, China.

For correspondence:- Jiaoe Liao Email: Jiaoedr513@outlook.com

Accepted: 12 June 2022 Published: 31 July 2022

Citation: Xiao L, Liao J. Effect of combined use of atorvastatin and hormonal therapy on serum prostate-specific antigen, urinary function, and quality of life of early prostate cancer patients in intensive care unit. Trop J Pharm Res 2022; 21(7):1549-1555 doi: 10.4314/tjpr.v21i7.27

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the effects of combined use of atorvastatin and hormonal therapy on serum levels of prostate-specific antigen (PSA), urinary function parameters, and quality of life (QOL) of intensive care unit (ICU) patients with early prostate cancer (PCa).

Methods: The clinical data for 90 PCa patients treated in ICU of Chenzhou First People's Hospital, Chenzhou, China from July 2019 to July 2020 were retrospectively analyzed. The patients were divided into a reference group given intensity-modulated radiotherapy (n = 45), and a study group treated with intensity-modulated radiotherapy + atorvastatin + hormonal therapy (n = 45) sequentially as they were admitted. After the treatments, serum PSA levels of the patients were measured using enzyme-linked immunosorbent assay (ELISA), while QOL was measured based on Expanded Prostate Cancer Index Composite (EPIC). Urinary parameters were determined by measuring various urodynamic indicators.

Results: Compared with the reference group, the study group had significantly lower post-treatment serum levels of PSA and blood lipids, higher levels of urinary function indicators (except for residual urine volume), and higher scores in IIEF-5 and EPIC (p < 0.001).

Conclusion: These results demonstrate that the combined use of atorvastatin and hormonal therapy is a reliable method for improving urinary function and QOL in early PCa patients. Moreover, the combined treatment has potentials for reducing serum levels of PSA and blood lipids in PCa patients. These findings may be useful in the establishment of improved therapy for early PCa.

Keywords: Atorvastatin, Hormonal therapy, Early prostate cancer, Serum PSA, Urinary function, Quality of life